Compare Honest Company Inc (HNST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Honest Company Inc trades at $5.05 (market cap $533.20M), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 19× Honest Company Inc's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,990,155). Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HNST | XBI | |
|---|---|---|
Market Cap | $533.20M | $10.11B |
Volume | 1,990,155 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $5.95 | $169.55 |
52-Week Low | $2.10 | $104.99 |
Typical Hold Time | 39 Days | 38 Days |
Enterprise Value | $436.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
